A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Boehringer Ingelheim

Status and phase: Completed; Phase 2

Conditions: Wet Macular Degeneration

Treatments: Drug: BI 144807

Study type: Interventional

Funder types: Industry

Identifiers

NCT02121522

1313.20

2013-004567-30 (EudraCT Number)

Details and patient eligibility

About

The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients. A further objective is to collect data on adverse events, vital signs, ECG and clinical laboratory parameters of BI 144807 in the same patient group.

Enrollment: 14 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Newly diagnosed men and women with unilateral subfoveal choroideal neovascularization secondary to age-related macular degeneration

Exclusion criteria

Additional eye disease that could compromizse best corrected visual acuity, such as uncontrolled glaucoma

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

BI 144807

Experimental group

Description:

twice daily

Treatment:

Drug: BI 144807